• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

推荐较低剂量的伯氨喹啉作为常见 G6PD 缺乏地区疟原虫配子体杀灭剂的理由。

Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common.

机构信息

Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

出版信息

Malar J. 2012 Dec 14;11:418. doi: 10.1186/1475-2875-11-418.

DOI:10.1186/1475-2875-11-418
PMID:23237606
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3546849/
Abstract

In areas of low malaria transmission, it is currently recommended that a single dose of primaquine (0.75 mg base/kg; 45 mg adult dose) be added to artemisinin combination treatment (ACT) in acute falciparum malaria to block malaria transmission. Review of studies of transmission-blocking activity based on the infectivity of patients or volunteers to anopheline mosquitoes, and of haemolytic toxicity in glucose 6-dehydrogenase (G6PD) deficient subjects, suggests that a lower primaquine dose (0.25 mg base/kg) would be safer and equally effective. This lower dose could be deployed together with ACTs without G6PD testing wherever use of a specific gametocytocide is indicated.

摘要

在疟疾传播水平较低的地区，目前建议在青蒿素类复方疗法（ACT）治疗急性间日疟时，增加一剂伯氨喹（0.75 毫克碱基/公斤；45 毫克成人剂量），以阻断疟疾传播。对基于患者或志愿者对按蚊感染性和葡萄糖-6-磷酸脱氢酶（G6PD）缺乏受试者溶血性毒性的研究进行综述后提示，较低剂量的伯氨喹（0.25 毫克碱基/公斤）更安全且同样有效。这种较低剂量可以与 ACT 一起使用，而无需在 G6PD 检测情况下在所有需要使用特定配子体杀灭剂的地方使用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b492/3546849/25f910bafefe/1475-2875-11-418-6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b492/3546849/cf1f09719f72/1475-2875-11-418-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b492/3546849/26bca1d5124d/1475-2875-11-418-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b492/3546849/2928fa0f8163/1475-2875-11-418-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b492/3546849/0008b50781b7/1475-2875-11-418-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b492/3546849/1f47e98cfdbd/1475-2875-11-418-5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b492/3546849/25f910bafefe/1475-2875-11-418-6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b492/3546849/cf1f09719f72/1475-2875-11-418-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b492/3546849/26bca1d5124d/1475-2875-11-418-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b492/3546849/2928fa0f8163/1475-2875-11-418-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b492/3546849/0008b50781b7/1475-2875-11-418-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b492/3546849/1f47e98cfdbd/1475-2875-11-418-5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b492/3546849/25f910bafefe/1475-2875-11-418-6.jpg

相似文献

1
Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common.推荐较低剂量的伯氨喹啉作为常见 G6PD 缺乏地区疟原虫配子体杀灭剂的理由。
Malar J. 2012 Dec 14;11:418. doi: 10.1186/1475-2875-11-418.
2
Single Low Dose Primaquine (0.25 mg/kg) Does Not Cause Clinically Significant Haemolysis in G6PD Deficient Subjects.单次低剂量伯氨喹（0.25毫克/千克）不会在葡萄糖-6-磷酸脱氢酶（G6PD）缺乏的受试者中引起具有临床意义的溶血。
PLoS One. 2016 Mar 24;11(3):e0151898. doi: 10.1371/journal.pone.0151898. eCollection 2016.
3
Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission.用于减少恶性疟原虫传播的伯氨喹或其他8-氨基喹啉类药物。
Cochrane Database Syst Rev. 2018 Feb 2;2(2):CD008152. doi: 10.1002/14651858.CD008152.pub5.
4
Primaquine for reducing Plasmodium falciparum transmission.伯氨喹用于减少恶性疟原虫传播。
Cochrane Database Syst Rev. 2012 Sep 12(9):CD008152. doi: 10.1002/14651858.CD008152.pub2.
5
The effect of single low-dose primaquine treatment for uncomplicated Plasmodium falciparum malaria on haemoglobin levels in Ethiopia: a longitudinal cohort study.单剂低剂量磷酸萘酚喹治疗无并发症恶性疟原虫疟疾对埃塞俄比亚血红蛋白水平的影响：一项纵向队列研究。
Malar J. 2024 Jul 12;23(1):208. doi: 10.1186/s12936-024-05021-x.
6
Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open-label randomized trial.单剂量伯氨喹减少柬埔寨配子体携带和恶性疟原虫传播：一项开放标签随机试验。
PLoS One. 2017 Jun 7;12(6):e0168702. doi: 10.1371/journal.pone.0168702. eCollection 2017.
7
Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries.使用伯氨喹和葡萄糖-6-磷酸脱氢酶缺乏症检测：疟疾流行国家的不同政策和做法。
PLoS Negl Trop Dis. 2018 Apr 19;12(4):e0006230. doi: 10.1371/journal.pntd.0006230. eCollection 2018 Apr.
8
Anti-infectivity efficacy and pharmacokinetics of WHO recommended single low-dose primaquine in children with acute Plasmodium falciparum in Burkina Faso: study protocol.世卫组织推荐的单剂低剂量伯氨喹在布基纳法索急性恶性疟原虫感染儿童中的抗感染力疗效和药代动力学：研究方案。
Trials. 2024 Sep 3;25(1):583. doi: 10.1186/s13063-024-08428-8.
9
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.在坦桑尼亚，与青蒿素联合使用一剂伯氨喹后发生的溶血并不仅限于葡萄糖-6-磷酸脱氢酶缺乏症（G6PD A-）个体。
Antimicrob Agents Chemother. 2010 May;54(5):1762-8. doi: 10.1128/AAC.01135-09. Epub 2010 Mar 1.
10
Primaquine: the risks and the benefits.伯氨喹：风险与益处
Malar J. 2014 Nov 3;13:418. doi: 10.1186/1475-2875-13-418.

引用本文的文献

1
Single low-dose primaquine for malaria control in Africa: a systematic review of safety, efficacy and implementation barriers.非洲使用单剂量低剂量伯氨喹控制疟疾：安全性、疗效及实施障碍的系统评价
BMJ Glob Health. 2025 Aug 14;10(8):e020264. doi: 10.1136/bmjgh-2025-020264.
2
Single low dose primaquine to block the transmission of Plasmodium falciparum-proposed stand-alone and ACT-adapted regimens.单剂量低剂量伯氨喹阻断恶性疟原虫传播——拟用的单独用药方案和与青蒿素联合疗法适配的方案
BMC Med. 2025 Jul 1;23(1):397. doi: 10.1186/s12916-025-04153-4.
3
Effect of mass drug administration on malaria incidence in southeast Senegal during 2020-22: a two-arm, open-label, cluster-randomised controlled trial.

本文引用的文献

1
Primaquine to prevent transmission of falciparum malaria.伯氨喹预防恶性疟传播。
Lancet Infect Dis. 2013 Feb;13(2):175-81. doi: 10.1016/S1473-3099(12)70198-6. Epub 2012 Nov 23.
2
G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map.G6PD 缺乏症在疟疾流行国家的流行率和受影响人群估计：基于地统计学模型的地图。
PLoS Med. 2012;9(11):e1001339. doi: 10.1371/journal.pmed.1001339. Epub 2012 Nov 13.
3
Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone.
2020 - 2022年期间大规模药物给药对塞内加尔东南部疟疾发病率的影响：一项双臂、开放标签、整群随机对照试验。
Lancet Infect Dis. 2025 Jun;25(6):656-667. doi: 10.1016/S1473-3099(24)00741-2. Epub 2025 Jan 9.
4
Artemisinin-resistant malaria.抗青蒿素疟疾
Clin Microbiol Rev. 2024 Dec 10;37(4):e0010924. doi: 10.1128/cmr.00109-24. Epub 2024 Oct 15.
5
Recent Advancement in Drug Development for Treating Malaria using Herbal Medicine and Nanotechnological Approach.利用草药和纳米技术方法治疗疟疾的药物研发最新进展
Curr Pharm Des. 2025;31(3):203-218. doi: 10.2174/0113816128321468240828103439.
6
Anti-infectivity efficacy and pharmacokinetics of WHO recommended single low-dose primaquine in children with acute Plasmodium falciparum in Burkina Faso: study protocol.世卫组织推荐的单剂低剂量伯氨喹在布基纳法索急性恶性疟原虫感染儿童中的抗感染力疗效和药代动力学：研究方案。
Trials. 2024 Sep 3;25(1):583. doi: 10.1186/s13063-024-08428-8.
7
Bioequivalence of a new coated 15 mg primaquine formulation for malaria elimination.用于消除疟疾的新型包衣 15 毫克磷酸萘酚喹制剂的生物等效性。
Malar J. 2024 Jun 5;23(1):176. doi: 10.1186/s12936-024-04947-6.
8
Updates on traditional methods for combating malaria and emerging -based interventions.对抗疟疾的传统方法和新兴干预措施的最新进展。
Front Cell Infect Microbiol. 2024 Apr 23;14:1330475. doi: 10.3389/fcimb.2024.1330475. eCollection 2024.
9
Prevalence of G6PD deficiency and submicroscopic malaria parasites carriage in malaria hotspot area in Northwest, Tanzania.坦桑尼亚西北部疟疾热点地区葡萄糖-6-磷酸脱氢酶（G6PD）缺乏症和亚临床疟原虫携带率。
Malar J. 2023 Dec 7;22(1):372. doi: 10.1186/s12936-023-04801-1.
10
Factors affecting haemoglobin dynamics in African children with acute uncomplicated Plasmodium falciparum malaria treated with single low-dose primaquine or placebo.影响用单剂低剂量伯氨喹或安慰剂治疗的无并发症急性恶性疟原虫疟疾非洲儿童血红蛋白动态变化的因素。
BMC Med. 2023 Oct 20;21(1):397. doi: 10.1186/s12916-023-03105-0.
葡萄糖-6-磷酸脱氢酶缺乏症患儿接受氨苯砜治疗后溶血性贫血的临床谱和严重程度。
Blood. 2012 Nov 15;120(20):4123-33. doi: 10.1182/blood-2012-03-416032. Epub 2012 Sep 19.
4
Primaquine for reducing Plasmodium falciparum transmission.伯氨喹用于减少恶性疟原虫传播。
Cochrane Database Syst Rev. 2012 Sep 12(9):CD008152. doi: 10.1002/14651858.CD008152.pub2.
5
Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study.泰国西部边境地区青蒿素耐药疟疾的出现：一项纵向研究。
Lancet. 2012 May 26;379(9830):1960-6. doi: 10.1016/S0140-6736(12)60484-X. Epub 2012 Apr 5.
6
Review: Improving the therapeutic index of 8-aminoquinolines by the use of drug combinations: review of the literature and proposal for future investigations.综述：通过联合用药提高 8-氨基喹啉类药物的治疗指数：文献回顾与未来研究建议。
Am J Trop Med Hyg. 2011 Dec;85(6):1010-4. doi: 10.4269/ajtmh.2011.11-0498.
7
Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination.疟原虫配子体与疟疾控制和消除相关的流行病学和感染力。
Clin Microbiol Rev. 2011 Apr;24(2):377-410. doi: 10.1128/CMR.00051-10.
8
[Widespread use of primaquine for control of Plasmodium vivax epidemics in a population with varying degrees of G6PD deficiency].[在具有不同程度葡萄糖-6-磷酸脱氢酶（G6PD）缺乏的人群中广泛使用伯氨喹控制间日疟流行]
Med Parazitol (Mosk). 2010 Oct-Dec(4):24-8.
9
Artemisinin resistance--the clock is ticking.青蒿素耐药性——时间紧迫。
Lancet. 2010 Dec 18;376(9758):2051-2. doi: 10.1016/S0140-6736(10)61963-0.
10
Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial.五种含青蒿素联合治疗方案与不含伯氨喹方案治疗无并发症恶性疟的效果比较：一项开放标签随机试验。
Lancet Infect Dis. 2010 Oct;10(10):673-81. doi: 10.1016/S1473-3099(10)70187-0. Epub 2010 Sep 9.